The Aortic Valve Stenosis drugs in development market research report provides comprehensive information on the therapeutics under development for Aortic Valve Stenosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Aortic Valve Stenosis. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Aortic Valve Stenosis and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Aortic Valve Stenosis by seven companies/universities/institutes. The top development phase for Aortic Valve Stenosis is preclinical with four drugs in that stage. The Aortic Valve Stenosis pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Aortic Valve Stenosis pipeline products market are: Abcentra, Vifor Pharma Management and Novartis.

The key targets in the Aortic Valve Stenosis pipeline products market include Apolipoprotein B 100 (ApoB100) , Apolipoprotein A (APOA or LPA), and Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5).

The key mechanisms of action in the Aortic Valve Stenosis pipeline product include Apolipoprotein B 100 (ApoB100) Inhibitor with three drugs in Preclinical. The Aortic Valve Stenosis pipeline products include two routes of administration with the top ROA being Oral and three key molecule types in the Aortic Valve Stenosis pipeline products market including Monoclonal Antibody, and Small Molecule.

Aortic Valve Stenosis overview

Aortic valve stenosis (AVS) is caused by narrowing of the heart’s aortic valve opening. The valve between the lower left heart chamber and the body’s main artery (aorta) is narrowed and doesn’t open fully, which obstructs blood flow from the heart into the aorta and onward to the rest of the body. AVS can range from mild to severe. Signs and symptoms may include chest pain, shortness of breath or fatigue, and increase in heart rate.

For a complete picture of Aortic Valve Stenosis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.